Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.58 |
| ▸ | KDR | P35968 | 6/20 | 0.55 |
| ▸ | KIT | P10721 | 4/20 | 0.55 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.55 |
| ▸ | LCK | P06239 | 2/20 | 0.55 |
| ▸ | LYN | P07948 | 2/20 | 0.55 |
| ▸ | FLT1 | P17948 | 2/20 | 0.55 |
| ▸ | FLT4 | P35916 | 2/20 | 0.55 |
| ▸ | FLT3 | P36888 | 2/20 | 0.55 |
| ▸ | BLK | P51451 | 2/20 | 0.55 |
| ▸ | AURKA | O14965 | 1/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.55 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.55 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.55 |
| ▸ | RET | P07949 | 1/20 | 0.55 |
| ▸ | PIM1 | P11309 | 1/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.55 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1703220 | 0.90 | KDR (0.53) | CYP3A4CYP3A5KDRKITPDGFRA | |
| SCHEMBL3442461 | 0.89 | CYP3A4 (0.60) | CYP3A4CYP3A5KDRKITPDGFRA | |
| SCHEMBL1703595 | 0.87 | CYP3A4 (0.58) | CYP3A4KDRKITPDGFRALCK | |
| SCHEMBL1703159 | 0.87 | KDR (0.60) | KDRKITPDGFRALCKLYN | |
| SCHEMBL1703153 | 0.86 | KDR (0.57) | CYP3A4CYP3A5KDRKITLCK | |
| SCHEMBL1702802 | 0.85 | KDR (0.57) | CYP3A4CYP3A5KDRKITPDGFRA | |
| SCHEMBL1703172 | 0.84 | KDR (0.56) | CYP3A4CYP3A5KDRKITPDGFRA | |
| SCHEMBL3443775 | 0.83 | KDR (0.50) | CYP3A4CYP3A5KDRKITPDGFRA | |
| SCHEMBL1703125 | 0.82 | KDR (0.60) | KDRKITLCKLYNFLT1 | |
| SCHEMBL1703490 | 0.81 | KIT (0.57) | CYP3A4CYP3A5KDRKITPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7812166-B2 | Kinase inhibitors | ABBOTT LABORATORIES (US) | 2010-10-12 | — | — | US | disclosed |
| EP-1807424-A2 | NOVEL KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2007-07-18 | — | — | EP | disclosed |
| US-20060178378-A1 | Novel kinase inhibitors | ABBVIE INC. | 2006-08-10 | — | — | US | disclosed |
| WO-2006050109-A2 | NOVEL KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178378-A1 | Novel kinase inhibitors | ABL1, MAP3K19, MAP3K20 | CYP3A4 4186/4885CYP3A5 3775/4885KDR 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.